| Today’s Big NewsOct 10, 2023 |
| By Max Bayer Biogen's new research chief Jane Grogan is looking to bring her recent biotech chops to a Big Pharma that's recalibrating. Her appointment follows a summer marked by layoffs, restructuring and a big-time acquisition. |
|
|
|
By Angus Liu What doctors described as a “messy” treatment landscape in early-stage non-small cell lung cancer could get clearer thanks to a first-in-class overall survival win from Merck & Co.’s Keytruda. |
By Conor Hale ANAHEIM, California—At the MedTech Conference, an FDA official described the tasks ahead as the agency moves to increase its oversight of lab-developed tests. |
By Gabrielle Masson Novartis rolled the dice in 2020 with a $210 upfront acquisition of long-time neuroscience partner Cadent Therapeutics. But the bet seems to have come up empty, as the Swiss pharma discontinues a mid-phase major depressive disorder program. |
|
Wednesday, October 18, 2023 | 11am ET / 8am PT Join industry experts for an exciting glimpse into the future of pharmaceutical innovation! Gain a comprehensive understanding of the latest strategies in organofluorine-based drug synthesis and learn key insights for staying ahead of the curve in this rapidly evolving landscape. Register now. 
|
|
By Nick Paul Taylor Akero Therapeutics’ nonalcoholic steatohepatitis (NASH) candidate has flunked a key test. The failure of FGF21 analog efruxifermin to significantly reduce fibrosis in cirrhotic NASH patients sent Akero’s stock tumbling—and caused fallout that dragged a rival’s share price down, too. |
By Andrea Park Ahead of a planned acquisition by Medtronic, it’s not all smooth sailing for insulin patch pump maker EOFlow. |
By Fraiser Kansteiner Despite the promise of cell therapies, manufacturing the personalized medicines at scale has been a limiting factor for many companies. Now, as BlueRock Therapeutics advances its lead prospect, its parent company Bayer is ready to kick production into high gear. |
By Annalee Armstrong After tweaking a phase 3 clinical trial for the ischemic stroke cell therapy MultiStem with the blessing of the FDA and moving forward with an enrollment goal of 300 patients, Athersys now reports that the sample size is insufficient to achieve the primary endpoint. |
By Conor Hale More than two years after purchasing the medical data aggregator Capsule Technologies, Philips is launching a newly integrated information platform capable of connecting nearly all of the devices used across a hospital. |
By Andrea Park For the first time, the FDA has given the green light to histotripsy technology, which uses focused ultrasound waves to noninvasively destroy a tumor. |
By Kevin Dunleavy Closing in on a likely approval to treat retinal vein occlusion, Roche has presented long-term data that show Vabysmo can maintain visual gains in the indication with a dosing duration stretched for some patients to as long as once every four months |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. |
|
|---|
|
|
|
Wednesday, November 1, 2023 | 1pm ET / 10am PT Join us to hear about a new, fully integrated and interoperable solution for Health at Home (Remote Care Delivery), with key insights on the journey from idea to market. You'll learn about EMR integration, managing data at scale, best practices on accelerating startup innovation, and much more. Register today! 
|
|
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Cell and gene therapy development has exploded, with Q4 2022 showing more FDA approvals than over the past five years combined.[1] Sponsored by: Thermo Fisher Scientific |
Webinar Embark on an in-depth journey through the pivotal Make-Test-Decide Workflow, where collaboration and data-driven decisions play a paramount role in the intricate landscape of drug discovery. Watch now to learn how cloud implementation fosters accessibility and collaboration, revolutionizing research across locations and companies. Sponsored by: Revvity Signals |
Whitepaper Economic and regulatory factors are making biopharma supply chains more complex in the EU. This paper explores strategies that biopharma companies can use to better manage complexity, cost, and risk. Presented by: AIM, the supply chain leader for life science entrants and midsize life science companies |
Whitepaper From Assay Development Through Large Molecule Development. Streamline your R&D workflows and gain valuable insights with our Biology Solutions Brochure. Download now to discover how to control your laboratory workflows across various assay techniques, modalities, and data types. Sponsored by: Revvity Signals |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
| Edison Ballroom, New York City |
|
|
| |
|
